专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009013324A9 VECTOR PARTICLES FOR TARGETING CD34+ CELLS 审中-公开
公开(公告)号：WO2009013324A9
公开(公告)日：2009-01-29
申请号：PCT/EP2008/059674
申请日：2008-07-23
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , COSSET, François-Loïc , VERHOEYEN, Els , COSTA, Caroline , FRECHA, Cecilia
发明人： COSSET, François-Loïc , VERHOEYEN, Els , COSTA, Caroline , FRECHA, Cecilia
IPC分类号： C12N15/867 , C12N7/00 , C07K14/52 , C12N15/12 , A61K48/00
摘要： The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least: -a first protein which comprises the transmembrane and extracellular domains of the feline endogenous RD114 virus envelope glycoprotein, and -a second protein which comprises a ligand of the c-Kit receptor.

2. 发明申请

WO2004078986A1 INFECTIOUS FLAVIVIRUS PSEUDO-PARTICLES CONTAINING FUNCTIONAL PRM AND/OR E PROTEINS 审中-公开
标题翻译：含有功能性PRM和/或E蛋白的感染性FLAVIVIRUS PSEUDO-颗粒
公开(公告)号：WO2004078986A1
公开(公告)日：2004-09-16
申请号：PCT/IB2004/000545
申请日：2004-03-02
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , BARTOSCH, Birke , COSSET, François-Loïc
发明人： BARTOSCH, Birke , COSSET, François-Loïc
IPC分类号： C12N15/86
CPC分类号： C12N15/86 , A61K48/00 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , C07K14/005 , C12N7/00 , C12N2740/13043 , C12N2740/13045 , C12N2770/24122 , C12N2770/24123 , C12N2810/60 , Y02A50/386 , Y02A50/388 , Y02A50/394
摘要： The invention relates to the generation and the use of flavivirus pseudo-particles containing native functional prM and E envelope glycoproteins assembled onto retroviral core particles. These particles are highly infectious and constitute a valid model of flavivirus virion whose handling does not require category 3 or 4 laboratories.
摘要翻译：本发明涉及包含装配在逆转录病毒核心颗粒上的天然功能性prM和E包膜糖蛋白的黄病毒假颗粒的产生和使用。这些颗粒是高度感染性的，构成黄病毒病毒粒子的有效模型，其处理不需要3或4类实验室。

3. 发明申请

WO2004024904A2 INFECTIOUS HEPACIVIRUS PSEUDO-PARTICLES CONTAINING FUNCTIONAL E1, E2 ENVELOPE PROTEINS 审中-公开
标题翻译：含有功能性E1，E2包膜蛋白的感染性乙型肝炎病毒颗粒
公开(公告)号：WO2004024904A2
公开(公告)日：2004-03-25
申请号：PCT/IB2003/003882
申请日：2003-09-12
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , BARTOSCH, Birke , COSSET, François-Loïc
发明人： BARTOSCH, Birke , COSSET, François-Loïc
IPC分类号： C12N7/00
CPC分类号： A61K39/29 , A61K39/12 , A61K48/00 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , C07K14/005 , C12N7/00 , C12N2710/16143 , C12N2740/13022 , C12N2740/13023 , C12N2740/13034 , C12N2770/24222 , C12N2770/24223 , C12N2770/24234 , C12N2770/24245 , C12N2810/609 , G01N33/566 , G01N2333/186 , G01N2500/10
摘要： The invention relates to the generation and the use of hepacivirus pseudo-particles containing native functional E1, E2 envelope glycoproteins assembled onto retroviral core particles. These particles are highly infectious and constitute a valid model of hepacivirus viríon.
摘要翻译：本发明涉及含有天然功能性E1，E2包膜糖蛋白的组合在逆转录病毒核心颗粒上的肝病毒假颗粒的产生和使用。这些颗粒是高度感染性的，构成了一种有效的肝炎病毒模型。

4. 发明申请

WO2013045639A1 LENTIVIRAL VECTORS PSEUDOTYPED WITH MUTANT BaEV GLYCOPROTEINS 审中-公开
标题翻译：生物活性成分与突变型白蛋白
公开(公告)号：WO2013045639A1
公开(公告)日：2013-04-04
申请号：PCT/EP2012/069230
申请日：2012-09-28
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , ECOLE NORMALE SUPERIEURE DE LYON
发明人： GIRARD-GAGNEPAIN, Anais , VERHOEYEN, Els , LAVILLETTE, Dimitri , COSSET, François-Loïc
IPC分类号： C12N15/867 , C07K14/15 , A61K48/00
CPC分类号： C12N15/86 , A61K48/00 , C07K14/005 , C07K2319/00 , C12N2740/13022 , C12N2740/15043 , C12N2740/15045 , C12N2740/16043 , C12N2740/16045 , C12N2810/6054
摘要： The present invention concerns a pseudotyped viral vector particle for transferring biological material into cells, wherein said vector particle comprises at least: - a chimeric envelope glycoprotein which comprises or consists in a fusion of the transmembrane and extracellular domain of a baboon endogenous retrovirus (BaEV) envelope glycoprotein and the cytoplasmic tail domain of a murine leukemia virus (MLV) envelope glycoprotein; or - a modified BaEV envelope glycoprotein wherein the cytoplasmic tail domain is devoid of the fusion inhibitory R peptide.
摘要翻译：本发明涉及用于将生物材料转移到细胞中的假型病毒载体颗粒，其中所述载体颗粒至少包含： - 嵌合包膜糖蛋白，其包含或组成狒狒内源性逆转录病毒（BaEV）的跨膜和细胞外结构域的融合物，包膜糖蛋白和鼠白血病病毒（MLV）包膜糖蛋白的胞质尾区; 或 - 修饰的BaEV包膜糖蛋白，其中细胞质尾结构域缺乏融合抑制性R肽。

5. 发明申请

WO2017182585A1 METHODS FOR SELECTIVELY MODULATING THE ACTIVITY OF DISTINCT SUBTYPES OF CELLS 审中-公开
标题翻译：选择性调节细胞不同亚型活性的方法
公开(公告)号：WO2017182585A1
公开(公告)日：2017-10-26
申请号：PCT/EP2017/059435
申请日：2017-04-20
申请人： ECOLE NORMALE SUPERIEURE DE LYON , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITÉ CLAUDE BERNARD LYON 1 , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
发明人： COSTA FEJOZ, Caroline , VERHOEYEN, Els , COSSET, François-Loïc , BENDER, Ruben , BUCHHOLZ, Christian , ZHOU, Qi
IPC分类号： C12N15/86
摘要： The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.
摘要翻译：本发明涉及假型逆转录病毒样颗粒或逆转录病毒载体，其包含融合至细胞靶向性结构域并融合至功能性结构域的衍生自副粘病毒科家族病毒的工程化包膜糖蛋白。本发明还涉及所述假型逆转录病毒样颗粒或逆转录病毒载体选择性调节特定细胞亚群，特别是特定免疫细胞活性的用途。这些假型逆转录病毒样颗粒或逆转录病毒载体对于基因治疗，免疫治疗和/或疫苗接种特别有用。

6. 发明申请

WO2017005923A1 LENTIVIRAL VECTOR EXPRESSING MEMBRANE-ANCHORED OR SECRETED ANTIBODY 审中-公开
标题翻译：表达载体表达的膜载体或分泌的抗体
公开(公告)号：WO2017005923A1
公开(公告)日：2017-01-12
申请号：PCT/EP2016/066349
申请日：2016-07-08
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , UNIVERSITÉ CLAUDE BERNARD LYON 1 , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , ECOLE NORMALE SUPERIEURE DE LYON
发明人： FUSIL, Floriane , VERHOEYEN, Els , DEFRANCE, Thierry , COSSET, François-Loïc
IPC分类号： C12N15/86 , C07K16/10 , A61K39/29
CPC分类号： C12N15/86 , A61K39/29 , A61K2039/505 , A61K2039/5256 , C07K16/00 , C07K16/109 , C07K2317/10 , C07K2317/76 , C07K2319/03 , C12N2740/15043 , C12N2810/6054 , C12N2830/008 , C12N2830/20 , C12N2830/42 , C12N2830/48 , C12N2830/50
摘要： The invention concerns a multicistronic nucleic acid, in particular an isolated multicistronic nucleic acid, comprising: A) a sequence comprising successively: A1) a sequence encoding the light chain variable domain of an antibody of interest, fused in the frame with A2) a sequence encoding the constant region of the light chain of an immunoglobulin Ig; and B) a sequence comprising successively: B1) a sequence encoding the heavy chain variable domain of said antibody of interest, fused in the frame with B2) a sequence encoding the constant regions of the heavy chain of an immunoglobulin Ig' in secretory form; B3) an intronic sequence of the gene of the heavy chain of said immunoglobulin Ig', said intronic sequence comprising an internal 5' splice site enabling the splicing of said intronic sequence B3) and a secretory-specific poly(A) (p AS) signal from the 3' terminal exon of said gene; B4) a sequence, in frame with sequence B1), encoding the transmembrane and cytoplasmic domains M1 and M2 of the immunoglobulin Ig' BCR, wherein said sequence B4) comprises, between the coding sequences of the M1 and M2 domains, an intronic sequence containing a splice site enabling the splicing of said intronic sequence between the M1 and M2 domains coding sequences; and B5) a membrane-anchored specific poly(A) signal (p AM), after the stop codon of the M2 domain, wherein the multicistronic nucleic acid enables the co-expression of the sequences A and B into separate proteins.
摘要翻译：本发明涉及多顺反子核酸，特别是分离的多顺反子核酸，其包含：A）连续包含的序列：A1）编码感兴趣抗体的轻链可变结构域的序列，其融合在框架中A2）序列编码免疫球蛋白Ig的轻链的恒定区; 和B）连续包含的序列：B1）编码所述感兴趣抗体的重链可变结构域的序列，其与所述框架融合在一起; B2）编码分泌形式的免疫球蛋白Ig'的重链恒定区的序列; B3）所述免疫球蛋白Ig'的重链基因的内含子序列，所述内含子序列包含能够剪接所述内含子序列B3）和分泌特异性聚（A）（p AS）的内部5'剪接位点，来自所述基因的3'末端外显子的信号; B4）编码免疫球蛋白Ig'BCR的跨膜和胞质结构域M1和M2的序列，其中序列B1），其中所述序列B4）在M1和M2结构域的编码序列之间包含含有所述剪接位点能够在M1和M2结构域编码序列之间剪接所述内含子序列; 和B5）M2结构域的终止密码子之后的膜锚定的特异性聚（A）信号（pAM），其中所述多顺反子核酸能够使序列A和B共同表达成分离的蛋白质。

7. 发明公开

EP3235908A1 METHODS FOR SELECTIVELY MODULATING THE ACTIVITY OF DISTINCT SUBTYPES OF CELLS 审中-公开
标题翻译：选择性调节细胞不同亚型活性的方法
公开(公告)号：EP3235908A1
公开(公告)日：2017-10-25
申请号：EP16305468.7
申请日：2016-04-21
申请人： ECOLE NORMALE SUPERIEURE DE LYON , Centre National de la Recherche Scientifique , Université Claude Bernard Lyon 1 , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
发明人： COSTA FEJOZ, Caroline , VERHOEYEN, Els , COSSET, François-Loïc , BENDER, Ruben , BUCHHOLZ, Christian , ZHOU, Qi
IPC分类号： C12N15/86
CPC分类号： C12N15/86 , C07K2319/03 , C07K2319/74 , C12N2740/16043 , C12N2740/16045 , C12N2760/18222 , C12N2760/18422
摘要： The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain.
The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.
摘要翻译：本发明涉及假型逆转录病毒样颗粒或逆转录病毒载体，其包含融合至细胞靶向性结构域并融合至功能性结构域的衍生自副粘病毒科家族病毒的工程化包膜糖蛋白。本发明还涉及所述假型逆转录病毒样颗粒或逆转录病毒载体选择性调节特定细胞亚群，特别是特定免疫细胞活性的用途。这些假型逆转录病毒样颗粒或逆转录病毒载体对于基因治疗，免疫治疗和/或疫苗接种特别有用。

8. 发明申请

WO2012093234A2 ARABINOGALACTANES SULFATES, APIOGALACTURONANES ET HETEROGLYCANES SULFATES POUR LE TRAITEMENT DES MALADIES CAUSEES PAR LES VIRUS INFLUENZA 审中-公开
标题翻译： Arabinogalactanes硫酸盐，APIOGALACTURONANES杂多糖的硫酸盐和用于疾病治疗由流感病毒
公开(公告)号：WO2012093234A2
公开(公告)日：2012-07-12
申请号：PCT/FR2012/050017
申请日：2012-01-03
申请人： ELICITYL , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - I.N.S.E.R.M. , COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES , LINA, Bruno , FERRARIS, Olivier , VO, Ho Hong Hai , COSSET, François-Loïc , SZECSI, Judit , HEYRAUD, Alain , LORTAT-JACOB, Hugues , BARTOLI, Julia , SADIR, Rabia , LIVACHE, Thierry , DARBLADE, Benoît , HAVET, Stéphane , BONNET, Silvère
发明人： LINA, Bruno , FERRARIS, Olivier , VO, Ho Hong Hai , COSSET, François-Loïc , SZECSI, Judit , HEYRAUD, Alain , LORTAT-JACOB, Hugues , BARTOLI, Julia , SADIR, Rabia , LIVACHE, Thierry , DARBLADE, Benoît , HAVET, Stéphane , BONNET, Silvère
IPC分类号： A61K31/715 , A61K36/05 , A61K36/88 , A61P31/12 , A23L1/29
CPC分类号： A61K31/737 , A61K31/715 , A61K36/05 , A61K36/888
摘要： La présente invention concerne des polysaccharides choisis parmi les arabinogalactanes sulfatés, les apiogalacturonanes et les hétéroglycanes sulfates pour leur utilisation en tant que médicament dans le traitement, préventif ou curatif, d'un virus influenza, ainsi que les compositions pharmaceutiques comprenant, notamment en association avec au moins un excipient pharmaceutiquement acceptable : - soit un extrait de Codium fragile, comprenant des arabinogalactanes sulfatés, - soit un extrait de Zostera marina ou de Lemna minor comprenant des apiogalacturonanes, - soit un extrait de Caulerpa raœmosa comprenant des hétéroglycanes sulfates.
摘要翻译：
公关＆eacute;感受到来自arabinogalactanes sulfat eacute＆选择发明多糖; s时，apiogalacturonanes和h＆eacute; T＆eacute; roglycanes硫酸盐用作M＆eacute;药用产品在治疗，PR＆eacute;提夫或治愈性，流感病毒，以及药物组合物，其包括，尤其是结合至少一种药学上可接受的赋形剂： - 或者刺松藻，阿拉伯半乳聚糖含有sulfat（E S）的提取物， - 或大叶藻的提取物或青萍包括apiogalacturonanes， - 或蕨藻raœmosa的提取物包括H＆eacute; T＆eacute; roglycanes硫酸盐。

9. 发明申请

WO2004024190A2 RECOMBINANT LENTIVIRAL VECTOR PSEUDOTYPED WITH THE HA PROTEIN OF FPV, FOR GENE TRANSFER INTO THE RETINA 审中-公开
标题翻译：与HEMAGGLUTININ蛋白质合成的重组生物活性成分转基因转基因
公开(公告)号：WO2004024190A2
公开(公告)日：2004-03-25
申请号：PCT/EP2003/011815
申请日：2003-09-15
申请人： UNIVERSITE DE NANTES , ROLLING, Fabienne , COSSET, François-Loïc
发明人： ROLLING, Fabienne , COSSET, François-Loïc
IPC分类号： A61K48/00
CPC分类号： C12N15/86 , A61K48/0058 , C12N2740/15043 , C12N2740/15045 , C12N2810/60 , C12N2830/008
摘要： The present invention relates to a novel lentiviral vector particularly well shaped for performing gene transfer into the retina. These lentiviral vectors are pseudotyped with a HA protein from an orthomyxovirus and comprise one or several gene(s) useful for preventing or treating diseases of the eye. The invention also relates to compositions and methods for preventing or treating diseases of the eye, using the vector of the invention to transfer selected genes suitable for preventing or treating diseases of the eye.
摘要翻译：本发明涉及一种特别良好的用于进行基因转移到视网膜中的慢病毒载体。这些慢病毒载体用来自正粘病毒的HA蛋白质进行假型化，并且包含一种或几种可用于预防或治疗眼睛疾病的基因。本发明还涉及用于预防或治疗眼疾病的组合物和方法，使用本发明的载体转移适用于预防或治疗眼睛疾病的所选基因。

10. 发明申请

WO2006103493A1 METHODS FOR ENHANCING THE POTENCY OF HCV NEUTRALIZING ANTIBODIES 审中-公开
标题翻译：用于增强HCV中和抗体水平的方法
公开(公告)号：WO2006103493A1
公开(公告)日：2006-10-05
申请号：PCT/IB2005/004012
申请日：2005-12-21
申请人： EPIXIS , INSERM (Institut National de la Santé et de la Recherche Médicale) , ECOLE NORMALE SUPERIEURE DE LYON , UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI) , COSSET, François-Loïc , BARTOSCH, Birke , LAVILLETTE, Dimitri , DREUX, Marlène , KLATZMANN, David , DALBA, Charlotte
发明人： COSSET, François-Loïc , BARTOSCH, Birke , LAVILLETTE, Dimitri , DREUX, Marlène , KLATZMANN, David , DALBA, Charlotte
IPC分类号： G01N33/576
CPC分类号： G01N33/5767
摘要： The present invention relates to a method for selecting an HCV epitope which is not sensitive to HDL-mediated decrease of the neutralizing capacity of anti-HCV antibodies, as well as to methods for treating an HCV-infected patient or a subject who has been exposed to HCV, comprising administering to the patient a therapeutically effective amount of a compound inhibiting HCV/HDL/SR-BI interplay, or comprising reducing the plasma loads of HDL.
摘要翻译：本发明涉及一种选择对HDL介导的抗HCV抗体中和能力降低不敏感的HCV表位的方法，以及用于治疗已感染HCV感染的患者或受试者的方法包括向患者施用治疗有效量的抑制HCV / HDL / SR-BI相互作用的化合物，或包括降低HDL的血浆负荷。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式